When Genes Steal a Heartbeat: The Genetics of Sudden Cardiac Death

20% or more of sudden cardiac deaths in young individuals can be attributed to inherited genetic conditions. These are not the typical cases we associate with heart disease. Instead, the root lies in subtle molecular errors. The science is clear, and the tools are available. What is needed now is awareness and action to save lives

Recent weeks have seen a number of often heartbreaking news on otherwise apparently young and healthy individuals collapsing or having a cardiac arrest. In many of the cases, the individuals were young and hearty with no apparent heart disease or structural abnormality in autopsy.

These may not be isolated cases after all. Each year, thousands of such families across the world are faced with the same haunting question: Could this have been prevented? Sudden cardiac death (SCD) in young, particularly in individuals under the age of 35, often defies many of the prevalent beliefs. Unlike older individuals where coronary artery disease is the typical culprit, young victims often do not fall into the traditional risk categories. In these cases, traditional autopsies, if at all performed, do not provide much clarity or closure. That is why researchers and clinicians should now be shifting focus to the often-invisible culprit — genetic mutations that can alter the function of ion channels or disrupt the architecture of the heart muscle proteins. These molecular errors, inherited silently, can remain dormant and harmless for years until they are not triggered by factors such as fever, exercise, stress or certain medications. In such instances, the first symptom may tragically be the last.

Striking statistic

Recent genomic and autopsy studies have revealed a striking statistic: “at least 20% or more” of sudden cardiac deaths in young individuals can be attributed to inherited genetic conditions. These are not the typical cases we associate with heart disease — there is often no plaque, no blockages, and no visible damage. Instead, the root lies in subtle molecular errors affecting either the electrical conduction system commonly known as cardiac channelopathies or errors affecting the heart muscle itself, commonly known as cardiomyopathies. Channelopathies further can encompass a number of diseases like Long QT Syndrome (LQTS), Brugada Syndrome (BrS) to name a few, which disrupt the ion currents that maintain a stable heartbeat. And then there are cardiomyopathies, like hypertrophic and dilated forms, that alter the heart’s architecture and contractility at the cellular level.

What makes these even more complex is that carriers of these genetic mutations may appear completely healthy, have normal heart scans, appear normal during physical exams, and have no prior symptoms. The danger hides in plain sight, sometimes triggered only under specific conditions.  This is why these conditions are so devastating — they do not always announce their presence until it is too late and conventional cardiac evaluations often miss them entirely.

Genetics of an “invisible” disease

Traditional autopsies fail to detect these genetic abnormalities, especially in the case of cardiac channelopathies. But with the advent of next-generation sequencing (NGS), “molecular autopsy”, a postmortem genetic analysis can uncover variants in genes such as SCN5A, KCNQ1, RYR2 and others that regulate cardiac ion flow.

A widely discussed case from Columbia University involved a 13-year-old boy who died suddenly while playing soccer. His heart was structurally normal. A detailed review and postmortem genetic testing revealed a borderline prolonged QT interval; a sign of Long QT syndrome. The diagnosis helped assess his siblings’ risk, some of whom were subsequently found to carry the same pathogenic variant.

Screening the living: A life-saving cascade

Knowing the genetic cause is not just about closure, it is about prevention. When mutation is found in the deceased, it opens a critical window for proactive screening of first-degree relatives, many of whom may unknowingly carry the same genetic risk. This process of cascade testing allows for systematic evaluation of the family members through a combination of clinical assessments such as ECGs, echocardiography, and targeted genetic testing. These systematic approaches help stratify individuals based on their level of risk and guide lifesaving interventions. For some, it may mean initiating lifestyle modifications or medications like beta-blockers, while for others at higher risk implantable cardioverter-defibrillators (ICDs) may be recommended to prevent fatal arrhythmias.

Early identification through such family-based screening has been shown to significantly reduce the incidence of sudden cardiac events, transforming what could have been another tragedy into opportunity for survival and long-term health. A recent study which performed genetic testing in close relatives of the deceased suggest a high diagnostic yield of 45.8%, suggesting genetic testing of family members of the deceased can indeed provide a unique opportunity to identify additional individuals who might be predisposed to the disease.

Why family history matters

While advanced genetic testing has become a powerful diagnostic tool, family history remains one of the most accessible and underutilised resources in identifying individuals at risk for inherited cardiac conditions. A research group from John Hopkins led by Prof. Daniel Judge. In a seminal 2012 paper, Dr. Daniel Judge and Boon Yew Tan from Johns Hopkins University emphasised the clinical value of constructing a three-generation pedigree, especially when evaluating unexplained sudden cardiac death or suspected inherited heart disease. A thorough family history not only helps uncover potential genetic patterns but can guide decisions around cascade testing and surveillance for other at risk-relatives.

However, this critical step is often overlooked in routine clinical practice. Busy outpatient settings, limited time, and low awareness about inherited arrhythmia syndromes contribute to missed opportunities. Additionally, families may describe past deaths using broad or imprecise terms like heart attack or cardiac arrest, which can obscure the true cause especially if no formal diagnosis or autopsy was ever performed. What may have actually been a fatal arrhythmia, cardiomyopathy, or aortic rupture is left hidden under vague terminologies.

Clarity in communication and deeper clinical probing, especially around symptoms such as fainting, seizures, or unexplained drownings, can unveil hidden inherited cardiac risk. Family history serves as a potential lifesaving diagnostic tool.

The Indian context: A wake-up call

In India, where health awareness and access to genetic counselling remain patchy, the burden is possibly underrecognised. With rising awareness and access to genomic services, especially in urban centres, we now have an opportunity to move from reactive to preventive medicine.  A recent study by Anjali Bajaj and others from CSIR-IGIB published in the journal Human Genomics, on the genetic prevalence of cardiac channelopathies suggests that over 1% of Indians have a genetic risk. Similarly, data from the All of US programme in the US estimates the prevalence of genetic variants associated with cardiomyopathy at 1.2% in the South Asian population (Circulation: Genomic and Precision Medicine). Putting together this suggests that the South Asian population is at a possibly higher genetic risk of developing cardiac channelopathies and cardiomyopathy. Therefore, pre-emptive screening of high-risk individuals and also individuals who might benefit from the knowledge, including athletes should enroll for clinical as well as genetic risk assessments. We could learn from such programmes already implemented for athletes in countries like Italy.

Moving from reaction to prevention

A 2023 review in Journal of Clinical Medical Research makes this appeal explicit: “Identifying at-risk individuals before the first event is no longer a hope; it is an obligation, enabled by genomics and owed to every grieving family.”

This is no longer the era where we accept cardiac death in young as a tragic mystery. We know better and more importantly, we can do better. Advances in genomic science, molecular diagnostics and structured family history evaluation have equipped us with the tools to move from reactive medicine to practice prevention.

When a young person dies suddenly, it should not mark the end of the investigation; it must become the starting point of a comprehensive family-based clinical response. That single event is more than a personal loss; it is a clinical red flag, a call to action for identifying silent carriers to the same genetic risk.

Imagine a future where siblings of a sudden cardiac death victim are immediately funnelled into a precision care pathway. Where genetic screening is routine, not rare or optional. Where a death prompts not just grief, but a lifesaving cascade of information. The science is clear. The tools are available. What is needed now is awareness and action.

“Let every unexplained death trigger a deeper look into history, into the family and into the genome. It might just prevent the next.”